Taletrectinib Elicits Durable Responses in TKI-Naïve an

Taletrectinib continued to demonstrate meaningful efficacy in the form of a durable objective response rate and a high intracranial ORR with acceptable tolerability in both TKI-naïve and crizotinib-pretreated patients with ROS1-positive non–small cell lung cancer.

Related Keywords

China , Denmark , Shanghai , Tongji , Sichuan , Copenhagen , Køavn , Wei Li , Innovent Biologics Inc , Thoracic Cancer Institute , European Lung Cancer Congress , Tongji University School Of Medicine , Lung Cancer Congress , Medical Oncology , Shanghai Pulmonary Hospital , Tongji University School , Heart Therapeutics , Taletrectinib , Intracranial Orr , Activity , Tolerability , Tki Naïve , Crizotinib Xalkori Pretreated Patients , Ros1 Positive Non Small Cell Lung Cancer , Phase 2 Trusti Trial , 2023 European Lung Cancer Congress ,